TrialThe Lancet. Infectious diseases2013
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.
Marc Gurwith et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
97 papers cite itlatest 60 shown
this paperpooled ittrialcites it